Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Mindset Pharma (MSET) releases positive preclinical results of its proprietary next-generation DMT & 5-MeO-DMT compounds
  • Mindset’s Family 4 compounds, a group of patent-pending novel chemical entities that are inspired by DMT & 5-MeO-DMT, are exhibiting positive in vitro screening characteristics
  • Published data has suggested that activation of the 5-HT1A as well as 5-HT2C receptors may also play a significant role in contributing to the subjective and behavioural effects
  • Mindset has also completed in vitro absorption, distribution, metabolism and excretion profiling on a subset of the compounds from Family 4
  • Mindset Pharma Inc. (MSET) is down 3.64 per cent and is trading at C$0.53 at 3:23 pm ET

Mindset Pharma (MSET) has released positive preclinical results of its proprietary next-generation DMT & 5-MeO-DMT compounds.

Mindset Pharma’s Family 4 compounds, a group of patent-pending novel chemical entities that are inspired by DMT & 5-MeO-DMT, are exhibiting positive in vitro screening characteristics.

James Lanthier, CEO of Mindset, commented,

“N,N-dimethyltryptamine (DMT) & 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) are potent, short-acting psychedelic drugs that produce strong hallucinogenic effects.”

“DMT & 5-MeO-DMT analogs, optimized for reduced toxicity and improved pharmacokinetic and pharmacodynamic characteristics, could have considerable potential as next generation psychedelic medicines,” added Lanthier.

Published data has suggested that activation of the 5-HT1A as well as 5-HT2C receptors may also play a significant role in contributing to the subjective and behavioural effects implicated in depression, anxiety, mood regulation, substance misuse and eating disorders, among other CNS disorders, elicited by psychedelics.

Mindset has also completed in vitro absorption, distribution, metabolism and excretion profiling on a subset of the compounds from Family 4 and as expected, several compounds demonstrated relatively short durations of action compared to other classic psychedelics.

Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs.

Mindset Pharma Inc. (MSET) is down 3.64 per cent and is trading at C$0.53 at 3:23 pm ET.

More From The Market Herald

" Marvel Biosciences (TSXV:MRVL) developing novel non-hallucinogenic neuroplastic promoting compounds

Marvel Biosciences (MRVL) has launched a program to identify and develop agents that promote neuroplasticity without the risks or side effects of psychedelics.

" Entheon Biomedical (CSE:ENBI) provides corporate update

Entheon Biomedical (ENBI) is pleased to provide an update on its operations and progress on its strategic initiatives.
Small Pharma - CEO, Peter Rands.

" Small Pharma (TSXV:DMT) granted European patent

Small Pharma (DMT) has been granted a European patent, strengthening its ketamine-based patent portfolio.

" Levitee Labs (CSE:LVT) enters into credit facility for up to $12 Million

Levitee Labs Inc. (LVT) has entered into a financing agreement for up to $12 million to fund further business expansion.